Japan unit of Britain’s Jazz Pharma starts phase III trial of Cannabis

Image

Japan unit of Britain's Jazz Pharma starts phase III trial of cannabis drug

Cannabis News
December 15, 2022

TOKYO – The Japanese unit of Britain’s Jazz Pharmaceuticals PLC (JAZZ.O) said on Thursday it had started a phase III trial of a cannabis-based drug for epilepsy. The trial follows a recommendation by a health ministry panel in September to revise Japan’s drug laws to allow for the importation and



Read More: Japan unit of Britain’s Jazz Pharma starts phase III trial of Cannabis

Comments are closed, but trackbacks and pingbacks are open.